The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped. The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped. your-feed-science, Regulation and Deregulation of Industry, Clinical Trials, Falsification of Data, Alzheimer’s Disease, Drugs (Pharmaceuticals), Dementia, Academic and Scientific Journals, Securities and Commodities Violations, Cassava Sciences Inc, City University of New York, Food and Drug Administration, Securities and Exchange Commission, Wang, Hoau-Yan, United States NYT > Science
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
